Oxidative stress after uninephrectomy alters heart morphology in the apolipoprotein e -/- mouse

Journal of Hypertension

Volumn 26, Issue 11, 2008, Pages 2220-2229

  Piecha, Grzegorz ^a,b,c   Koleganova, Nadezda ^a,b   Gross, Marie Luise ^b   Geldyyev, Aman ^b   Ritz, Eberhard ^a  

^a Division of Pediatric Nephrology   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Cardiac microvessels; Myocardial fibrosis; Oxidative stress; Renal function

Indexed keywords

3 NITROTYROSINE; APOLIPOPROTEIN E; COLLAGEN TYPE 1; EBSELEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; TEMPOL; TRANDOLAPRIL; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; AMINE OXIDE; ANTIOXIDANT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INDOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; AORTA ATHEROSCLEROSIS; ARTICLE; CAPILLARY DENSITY; ENDOTHELIAL DYSFUNCTION; HEART FUNCTION; HEART MUSCLE; HEART MUSCLE FIBROSIS; INTERSTITIUM; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHAM PROCEDURE; UNINEPHRECTOMY; ANIMAL; ARTERIOSCLEROSIS; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECT; GENE SILENCING; GENETICS; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE; HEART VENTRICLE REMODELING; METABOLISM; MOUSE MUTANT; NEPHRECTOMY; PATHOLOGY; PHYSIOLOGY; SPIN LABELING;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIOXIDANTS; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; CYCLIC N-OXIDES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; GENE SILENCING; HEART VENTRICLES; INDOLES; MALE; MICE; MICE, KNOCKOUT; MYOCARDIUM; NEPHRECTOMY; OXIDATIVE STRESS; SPIN LABELS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 56049116224     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32830ef5e4     Document Type: Article

References (47)

1. Brugts JJ, Knetsch AM, Mattace-Raso FUS, Hofman A, Witteman JCM. Renal function and risk of myocardial infarction in an elderly population: the Rotterdam Study. Arch Intern Med 2005; 165:2659-2665.
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C-y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305.
3. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62:1524-1538.
4. Amann K, Breitbach M, Ritz E, Mall G. Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 1998; 9:1018-1022.
5. Henry RMA, Kostense PJ, BosG, Dekker JM, Nijpels G, Heine RJ, et al.Mild renal insufciency is associated with increased cardiovascular mortality: the Hoorn Study. Kidney Int 2002; 62:1402-1407.
6. Van Biesen W, De Bacquer D, Verbeke F, Delanghe J, Lameire N, Vanholder R. The glomerular filtration rate in an apparently healthyopulation and its relation with cardiovascular mortality during 10 years. Eur Heart J 2007; 28:478-483.
7. Amann K, Neimeier KA, Schwarz U, Tö rnig J, Matthias S, Orth SR, et al. Rats with moderate renal failure show capillary decit in heart but not skeletal muscle. Am J Kidney Dis 1997; 30:382-388.
8. Amann K, Kronenberg G, Gehlen F, Wessels S, Orth S, Munter K, et al. Cardiac remodelling in experimental renal failure - an immunohistochemical study. Nephrol Dial Transplant 1998; 13:1958-1966.
9. Tornig J, Amann K, Ritz E, Nichols C, Zeier M, Mall G. Arteriolar wall thickening, capillary rarefaction and interstitial brosis in the heart of rats with renal failure: the effects of ramipril, nifedipine and moxonidine. Jam Soc Nephrol 1996; 7:667-675.
10. Amann K, Tornig J, Buzello M, Kuhlmann A, Gross M-L, Adamczak M, et al. Effect of antioxidant therapy with dl-[alpha]-tocopherol on cardiovascular structure in experimental renal failure. Kidney Int 2002; 62:877-884.
11. Zhu X-Y, Daghini E, Chade AR, Rodriguez-Porcel M, Napoli C, Lerman A, Lerman LO. Role of oxidative stress in remodeling of the myocardial microcirculation in hypertension. Arterioscler Thromb Vasc Biol 2006; 26:1746-1752.
12. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58:1072-1083.
13. Schwarz U, Amann K, Orth SR, Simonaviciene A,Wessels S, Ritz E. Effect of 1,25(OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 1998; 53:1696-1705.
14. Mattfeldt T, Mall G, Gharehbaghi H, Mö ller P. Estimation of surface area and length with the orientator. J Microsc 1990; 159:301-317.
15. Gross M-L, Heiss N, Weckbach M, Hansen A, El-Shakmak A, Szabo A, et al. ACE-inhibition is superior to endothelin A receptor blockade in preventing abnormal capillary supply and brosis of the heart in experimental diabetes. Diabetologia 2004; 47:316-324.
16. Nabokov AV, Amann K,Wessels S, Munter K,Wagner J, Ritz E. Endothelin receptor antagonists Influence cardiovascular morphology in uremic rats. Kidney Int 1999; 55:512-519.
17. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-254.
18. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. J Am Soc Nephrol 2001; 12:1315-1325.
19. Kielstein JT, Boger RH, Bode-Boger SM, Frolich JC, Haller H, Ritz E, Fliser D. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002; 13:170-176.
20. Buzello M, Tornig J, Faulhaber J, Ehmke H, Ritz E, Amann K. The apolipoprotein E knockout mouse: a model documenting accelerated atherogenesis in uremia. J Am Soc Nephrol 2003; 14:311-316.
21. Buzello M, Haas CS, Hauptmann F, Gross ML, Faulhaber J, Schultze-Mosgau S, et al. No aggravation of renal injury in apolipoprotein E knockout mice (ApoE-/-) after subtotal nephrectomy. Nephrol Dial Transplant 2004; 19:566-573.
22. Ivanovski O, Szumilak D, Nguyen-Khoa T, Ruellan N, Phan O, Lacour B, et al. The antioxidant N-acetylcysteine prevents accelerated atherosclerosis in uremic apolipoprotein E knockout mice. Kidney Int 2005; 67:2288-2294.
23. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000; 355:1575-1581.
24. Kobayashi N, DeLano FA, Schmid-Schonbein GW. Oxidative stress promotes endothelial cell apoptosis and loss of microvessels in the spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 2005; 25:2114-2121.
25. Gealekman O, Brodsky SV, Zhang F, Chander PN, Friedli C, Nasjletti A, Goligorsky MS. Endothelial dysfunction as a modier of angiogenic response in Zucker diabetic fat rat: amelioration with Ebselen. Kidney Int 2004; 66:2337-2347.
26. Querejeta R, Lopez B, Gonzalez A, Sanchez E, Larman M, Martinez Ubago JL, Diez J. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial brosis. Circulation 2004; 110:1263-1268.
27. Diez J,GonzalezA, LopezB,QuerejetaR.Mechanismsof disease: pathologic structural remodeling ismore than adaptive hypertrophy in hypertensive heart disease. Nat Clin Pract Cardiovasc Med 2005; 2:209-216.
28. Kass DA, Bronzwaer JGF, PaulusWJ.What mechanisms underlie diastolic dysfunction in heart failure Circ Res 2004; 94:1533-1542.
29. Tomaselli GF, Zipes DP. What causes sudden death in heart failure Circ Res 2004; 95:754-763.
30. Saunders WB, Bayless KJ, Davis GE. MMP-1 activation by serine proteases and MMP-10 induces human capillary tubular network collapse and regression in 3D collagenmatrices. J Cell Sci 2005; 118:2325-2340.
31. Peterson JT, Hallak H, Johnson L, Li H, O'Brien PM, Sliskovic DR, et al. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 2001; 103:2303-2309.
32. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrixcomposition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006; 113:2089-2096.
33. Murdoch CE, Zhang M, Cave AC, Shah AM. NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. Cardiovasc Res 2006; 71:208-215.
34. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, Himmelfarb J. Increased prevalence of oxidant stress and infiammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004; 65:1009-1016.
35. Amann K, Tyralla K, Gross M-L, Schwarz U, Tornig J, Haas CS, et al. Cardiomyocyte loss in experimental renal failure: prevention by ramipril. Kidney Int 2003; 63:1708-1713.
36. Solomon SD, Rice MM, A. Jablonski K, Jose P, Domanski M, Sabatine M,et al. Renal function and effectiveness of angiotensin- converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the prevention of events with ace inhibition (PEACE) trial. Circulation 2006; 114:26-31.
37. Cheng T-H, Cheng P-Y, Shih N-L, Chen I-B, Wang DL, Chen J-J. Involvement of reactive oxygen species in angiotensin II-induced endothelin-1 gene expression in rat cardiac broblasts. J Am Coll Cardiol 2003; 42:1845-1854.
38. Wu S, Gao J, Ohlemeyer C, Roos D, Niessen H, Kottgen E, Gessner R. Activation of AP-1 through reactive oxygen species by angiotensin II in rat cardiomyocytes. Free Radic Biol Med 2005; 39:1601-1610.
39. Hannken T, Schroeder R, Stahl RAK, Wolf G. Angiotensin II-mediated expression of p27Kip1 and induction of cellular hypertrophy in renal tubular cells depend on the generation of oxygen radicals1. Kidney Int 1998; 54:1923-1933.
40. Schupp N, Schmid U, Rutkowski P, Lakner U, Kanase N, Heidland A, Stopper H. Angiotensin II-induced genomic damage in renal cells can be prevented by angiotensin II type 1 receptor blockage or radical scavenging. Am J Physiol Renal Physiol 2007; 292:F1427-1434.
41. Border WA, Noble NA. Transforming growth factor b in tissue brosis. N Engl J Med 1994; 331:1286-1292.
42. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, Imaizumi T. Transforming growth factor-{beta} function blocking prevents myocardial brosis and diastolic dysfunction in pressure-overloaded rats. Circulation 2002; 106:130-135.
43. Dikow R, Kihm LP, Zeier M, Kapitza J, Tornig J, Amann K, et al. Increased infarct size in uremic rats: reduced ischemia tolerance J Am Soc Nephrol 2004; 15:1530-1536.
44. Sasso FC, Carbonara O, Persico E, D'Ambrosio R, Coppola L, Nasti R, et al. Increased vascular endothelial growth factor mRNA expression in the heart of streptozotocin-induced diabetic rats. Metabolism 2003; 52:675-678.
45. Sasso FC, Torella D, Carbonara O, Ellison GM, Torella M, Scardone M, et al. Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type 2 diabetic patients with chronic coronary heart disease. J Am Coll Cardiol 2005; 46:827-834.
46. Kuroki M, Voest EE, Amano S, Beerepoot LV, Takashima S, Tolentino M, et al. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest 1996; 98:1667-1675.
47. Mann JFE, Lonn EM, Yi Q, Gerstein HC, Hoogwerf BJ, Pogue J, et al. Effects of vitamin E on cardiovascular outcomes in people with mild-to- moderate renal insufciency: results of the HOPE Study. Kidney Int 2004; 65:1375-1380.